Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Neurodegenerative DiseaseOrphan Drug

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1648907

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1648907

Duchenne Muscular Dystrophy Drugs

PUBLISHED:
PAGES: 220 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 4950
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 14850

Add to Cart

Description

Table of Contents

Global Duchenne Muscular Dystrophy Drugs Market to Reach US$29.7 Billion by 2030

The global market for Duchenne Muscular Dystrophy Drugs estimated at US$4.4 Billion in the year 2024, is expected to reach US$29.7 Billion by 2030, growing at a CAGR of 37.7% over the analysis period 2024-2030. Exon Skipping Therapy, one of the segments analyzed in the report, is expected to record a 42.6% CAGR and reach US$19.7 Billion by the end of the analysis period. Growth in the Steroid Therapy segment is estimated at 26.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.8 Billion While China is Forecast to Grow at 43.6% CAGR

The Duchenne Muscular Dystrophy Drugs market in the U.S. is estimated at US$1.8 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.4 Billion by the year 2030 trailing a CAGR of 43.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 30.9% and 30.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 32.5% CAGR.

Global Duchenne Muscular Dystrophy Drugs Market - Key Trends & Drivers Summarized

What Is Duchenne Muscular Dystrophy and Its Impact?

Duchenne Muscular Dystrophy (DMD) is a severe genetic disorder characterized by progressive muscle degeneration and weakness. It primarily affects boys, with symptoms typically appearing between the ages of two and five. The disease is caused by mutations in the dystrophin gene, which is essential for muscle function. Without dystrophin, muscle fibers are damaged and eventually replaced by fat and connective tissue. The progression of DMD leads to loss of ambulation, respiratory and cardiac complications, and significantly reduced life expectancy. The impact on patients and their families is profound, necessitating ongoing medical care and support.

How Are Treatment Approaches Evolving?

Treatment approaches for Duchenne Muscular Dystrophy are evolving rapidly, with advancements in genetic therapies, molecular drugs, and symptomatic treatments. Historically, corticosteroids have been the mainstay of DMD treatment, helping to slow muscle degeneration. However, recent years have seen significant progress in gene therapy and exon-skipping drugs, which aim to address the underlying genetic causes of DMD. These innovative therapies are designed to restore or replace the defective dystrophin gene, offering the potential for more effective and long-lasting treatment outcomes. Additionally, supportive therapies such as physical therapy, respiratory care, and cardiac management remain crucial for improving quality of life and managing disease complications.

What Role Do Clinical Trials and Regulatory Approvals Play?

Clinical trials and regulatory approvals are pivotal in the development and availability of new treatments for Duchenne Muscular Dystrophy. Rigorous clinical trials are essential for demonstrating the safety and efficacy of new therapies. These trials often involve multiple phases and require collaboration between researchers, healthcare providers, and patients. Regulatory bodies, such as the FDA and EMA, play a critical role in evaluating and approving new drugs, ensuring that they meet stringent safety and effectiveness standards. Accelerated approval pathways and orphan drug designations are often utilized to expedite the development of treatments for rare diseases like DMD, providing patients with earlier access to promising therapies.

What Factors Are Driving Market Growth?

The growth in the Duchenne Muscular Dystrophy drugs market is driven by several factors, including advancements in genetic research, increased funding and investment, and the rising prevalence of the disease. Technological innovations in gene editing and molecular biology are paving the way for more targeted and effective treatments. Increased funding from governments, non-profit organizations, and pharmaceutical companies is accelerating research and development efforts. The rising awareness and diagnosis of DMD are also contributing to market growth, as more patients seek treatment. Additionally, collaborations between biotech firms and academic institutions are fostering the development of innovative therapies. The regulatory environment, with initiatives to fast-track the approval of orphan drugs, is further supporting market expansion, providing hope for improved outcomes for patients with DMD.

SCOPE OF STUDY:

The report analyzes the Duchenne Muscular Dystrophy Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Segment (Exon Skipping, Steroid Therapy, Mutation Suppression, Other Segments)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 38 Featured) -

  • FibroGen, Inc.
  • ITALFARMACO S.p.A.
  • NS Pharma Inc.
  • PTC Therapeutics, Inc.
  • Sarepta Therapeutics, Inc.
  • Satellos Bioscience, Inc.
Show more
Product Code: MCP11652

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • A Prelude to Duchenne Muscular Dystrophy
    • Global Economic Update
    • Here's How Inflationary Pressures Affect the Economy
    • Here's What's Causing Inflationary Pressures in the Global Market
    • World Economic Growth Projections (Real GDP, Annual % Change) for the Years 2020 Through 2024
    • Competition
    • Product Development as Hallmark of Global Duchenne Muscular Dystrophy Market
    • Duchenne Muscular Dystrophy Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
    • Global Market Overview and Prospects
    • Global Duchenne Muscular Dystrophy Drugs Market Set for a Rapid Growth, Driven by Rising Prevalence
    • A Review of the Approved DMD Drugs
    • North America and Europe to Remain Lucrative Markets
    • Molecular Therapy, Hospital/Clinic & Hospital Pharmacy: Hale & Hearty Segments of Duchenne Muscular Dystrophy Market
    • Dynamic Factors Keeping Duchenne Muscular Dystrophy Market Growing
    • Market Drivers
    • Rising Incidence of DMD to Catalyze Growth
    • DMD Prevalence (in 100,000 Population) in Select Countries: 2020
    • High Uptake of Novel Therapies & Drugs
    • Market Restraints & Challenges
    • Lack of Standardization for Clinical Efficacy
    • Stringent Regulatory Regime
    • Market Opportunities
    • Product Developments & Rising Awareness
    • Surge in Clinical Trials to Launch Novel Options
    • Recent Market Activity
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising R&D Investment to Boost DMD Market
    • Select Therapy Candidates Under Development for Treating DMD
    • Growing Government Support Propels Market Expansion
    • Biologics - The Most Dynamic Segment of the Market
    • Blossoming of Gene Therapy in Duchenne Muscular Dystrophy Treatment Domain
    • Gene Therapy for DMD Treatment
    • Elevidys, The First Ground-breaking Gene Therapy for Treatment of Duchenne Muscular Dystrophy (DMD)
    • Children's National Hospital Starts Offering Newly Approved Gene Therapy for DMD
    • Promising Gene Therapies
    • Potential Side-Effects & Risks of Gene Therapies
    • Vamorolon Holds Potential to Lessen Health Risks Linked with Extended Use of Steriods
    • DT-DEC01 Offers Promise to Stabilize or Improve Motor Function
    • AOC 1044 Receives Orphan Drug Status for DMD44
    • Italfarmaco Group Announces NDA Acceptance for Givinostat Targeting Duchenne Muscular Dystrophy
    • Uptrend in Healthcare Expenditure Creates Substantial Opportunities
    • World Healthcare Expenditure (In US$ Trillion) for the Years 2019, 2021 & 2023
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Duchenne Muscular Dystrophy Drugs Market Analysis of Annual Sales in US$ Thousand for Years 2018 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Duchenne Muscular Dystrophy Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR
    • TABLE 4: World 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2018, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Exon Skipping by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Exon Skipping by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR
    • TABLE 7: World 12-Year Perspective for Exon Skipping by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Steroid Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Steroid Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR
    • TABLE 10: World 12-Year Perspective for Steroid Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Therapeutic Approaches by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Therapeutic Approaches by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR
    • TABLE 13: World 12-Year Perspective for Other Therapeutic Approaches by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR
    • TABLE 16: World 12-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Drug Store & Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Drug Store & Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR
    • TABLE 19: World 12-Year Perspective for Drug Store & Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR
    • TABLE 22: World 12-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 23: USA Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR
    • TABLE 25: USA 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy and Other Therapeutic Approaches for the Years 2018, 2025 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR
    • TABLE 28: USA 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies for the Years 2018, 2025 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR
    • TABLE 31: Canada 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy and Other Therapeutic Approaches for the Years 2018, 2025 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR
    • TABLE 34: Canada 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies for the Years 2018, 2025 & 2030
  • JAPAN
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR
    • TABLE 37: Japan 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy and Other Therapeutic Approaches for the Years 2018, 2025 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR
    • TABLE 40: Japan 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies for the Years 2018, 2025 & 2030
  • CHINA
    • TABLE 41: China Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR
    • TABLE 43: China 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy and Other Therapeutic Approaches for the Years 2018, 2025 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR
    • TABLE 46: China 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies for the Years 2018, 2025 & 2030
  • EUROPE
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Duchenne Muscular Dystrophy Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR
    • TABLE 49: Europe 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2018, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR
    • TABLE 52: Europe 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy and Other Therapeutic Approaches for the Years 2018, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR
    • TABLE 55: Europe 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies for the Years 2018, 2025 & 2030
  • FRANCE
    • TABLE 56: France Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR
    • TABLE 58: France 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy and Other Therapeutic Approaches for the Years 2018, 2025 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR
    • TABLE 61: France 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies for the Years 2018, 2025 & 2030
  • GERMANY
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR
    • TABLE 64: Germany 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy and Other Therapeutic Approaches for the Years 2018, 2025 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR
    • TABLE 67: Germany 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies for the Years 2018, 2025 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR
    • TABLE 70: Italy 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy and Other Therapeutic Approaches for the Years 2018, 2025 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR
    • TABLE 73: Italy 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies for the Years 2018, 2025 & 2030
  • UNITED KINGDOM
    • TABLE 74: UK Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR
    • TABLE 76: UK 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy and Other Therapeutic Approaches for the Years 2018, 2025 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR
    • TABLE 79: UK 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies for the Years 2018, 2025 & 2030
  • REST OF EUROPE
    • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Rest of Europe Historic Review for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR
    • TABLE 82: Rest of Europe 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy and Other Therapeutic Approaches for the Years 2018, 2025 & 2030
    • TABLE 83: Rest of Europe Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Rest of Europe Historic Review for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR
    • TABLE 85: Rest of Europe 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies for the Years 2018, 2025 & 2030
  • ASIA-PACIFIC
    • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Asia-Pacific Historic Review for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR
    • TABLE 88: Asia-Pacific 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy and Other Therapeutic Approaches for the Years 2018, 2025 & 2030
    • TABLE 89: Asia-Pacific Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Asia-Pacific Historic Review for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR
    • TABLE 91: Asia-Pacific 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies for the Years 2018, 2025 & 2030
  • REST OF WORLD
    • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of World Historic Review for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR
    • TABLE 94: Rest of World 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy and Other Therapeutic Approaches for the Years 2018, 2025 & 2030
    • TABLE 95: Rest of World Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of World Historic Review for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR
    • TABLE 97: Rest of World 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies for the Years 2018, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!